John Taylor III

Dr. John Taylor III

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in European Urology Focus
Verified
Journal Article
Closed access
NLNiyati Lobo
Niyati Lobo
SSShahrokh F. Shariat
Shahrokh F. Shariat
CGCharles Chuanhai Guo
Charles Chuanhai Guo
MFMario Ignacio Fernandez
Mario Ignacio Fernandez
WKWassim Kassouf
Wassim Kassouf
Ashish M. KamatAshish M. Kamat
Ashish M. Kamat

31 March 2020 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
JMJoshua J. Meeks
Joshua J. Meeks
HAHikmat A. Al-Ahmadie
Hikmat A. Al-Ahmadie
BFBishoy M. Faltas
Bishoy M. Faltas
JIJohn Taylor III
John Taylor III
TFThomas W. Flaig
Thomas W. Flaig
LDLars Dyrskjøt
Lars Dyrskjøt

1 October 2019 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
BWBenjamin L. Woolbright
Benjamin L. Woolbright
GRGaneshkumar Rajendran
Ganeshkumar Rajendran
RHRobert A. Harris
Robert A. Harris
JIJohn Taylor III
John Taylor III
Cancer cells use alterations of normal metabolic processes to sustain proliferation indefinitely. Transcriptional and posttranscriptional control of the pyruvate dehydrogenase kinase (PDK) family is one way in which cancer cells alter normal pyruvate metabolism to fuel proliferation. PDKs can phosphorylate and inactivate the pyruvate dehydrogenase complex (PDHC), which blocks oxidative metabolism of pyruvate by the mitochondria. This process is thought to enhance cancer cell growth by promoting anabolic pathways. Inhibition of PDKs induces cell death through increased PDH activity and subsequent increases in ROS production. The use of PDK inhibitors has seen widespread success as a potential therapeutic in laboratory models of multiple cancers; however, gaps still exist in our understanding of the biology of PDK regulation and function, especially in the context of individual PDKs. Efforts are currently underway to generate PDK-specific inhibitors and delineate the roles of individual PDK isozymes in specific cancers. The goal of this review is to understand the regulation of the PDK isozyme family, their role in cancer proliferation, and how to target this pathway therapeutically to specifically and effectively reduce cancer growth.

26 March 2019 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
JPJustin C. Penticuff
Justin C. Penticuff
BWBenjamin L. Woolbright
Benjamin L. Woolbright
TSThais M. Sielecki
Thais M. Sielecki
SWScott J. Weir
Scott J. Weir
JIJohn Taylor III
John Taylor III

1 September 2018 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
BWBenjamin L. Woolbright
Benjamin L. Woolbright
DCDharamainder Choudhary
Dharamainder Choudhary
AMAndrew Mikhalyuk
Andrew Mikhalyuk
CTCassandra Trammel
Cassandra Trammel
SSSambantham Shanmugam
Sambantham Shanmugam
JIJohn Taylor III
John Taylor III
Advanced bladder cancer remains a major source of mortality, with poor treatment options. Cisplatin-based chemotherapy is the standard treatment, however many patients are or become resistant. One potential cause of chemoresistance is the Warburg effect, a metabolic switch to aerobic glycolysis that occurs in many cancers. Upregulation of the pyruvate dehydrogenase kinase family (PDK1–PDK4) is associated with aerobic glycolysis and chemoresistance through inhibition of the pyruvate dehydrogenase complex (PDH). We have previously observed upregulation of PDK4 in high-grade compared with low-grade bladder cancers. We initiated this study to determine if inhibition of PDK4 could reduce tumor growth rates or sensitize bladder cancer cells to cisplatin. Upregulation of PDK4 in malignant bladder cancer cell lines as compared with benign transformed urothelial cells was confirmed using qPCR. Inhibition of PDK4 with dichloroacetate (DCA) resulted in increased PDH activity, reduced cell growth, and G0–G1 phase arrest in bladder cancer cells. Similarly, siRNA knockdown of PDK4 inhibited bladder cancer cell proliferation. Cotreatment of bladder cancer cells with cisplatin and DCA did not increase caspase-3 activity but did enhance overall cell death in vitro. Although daily treatment with 200 mg/kg DCA alone did not reduce tumor volumes in a xenograft model, combination treatment with cisplatin resulted in dramatically reduced tumor volumes as compared with either DCA or cisplatin alone. This was attributed to substantial intratumoral necrosis. These findings indicate inhibition of PDK4 may potentiate cisplatin-induced cell death and warrant further studies investigating the mechanism through which this occurs. Mol Cancer Ther; 17(9); 2004–12. ©2018 AACR.

15 August 2017 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
Ashish M. KamatAshish M. Kamat
Ashish M. Kamat
JBJoaquim Bellmunt
Joaquim Bellmunt
MGMatthew D. Galsky
Matthew D. Galsky
BKBadrinath R. Konety
Badrinath R. Konety
DLDonald L. Lamm
Donald L. Lamm
JRJonathan E. Rosenberg
Jonathan E. Rosenberg
The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Guérin (BCG), which activates the immune system to recognize and destroy malignant cells and has demonstrated durable clinical benefit. Urologic best-practice guidelines and consensus reports have been developed and strengthened based on data on the timing, dose, and duration of therapy from randomized clinical trials, as well as by critical evaluation of criteria for progression. However, these reports have not penetrated the community, and many patients do not receive appropriate therapy. Additionally, several immune checkpoint inhibitors have recently been approved for treatment of metastatic disease. The approval of immune checkpoint blockade for patients with platinum-resistant or -ineligible metastatic bladder cancer has led to considerations of expanded use for both advanced and, potentially, localized disease. To address these issues and others surrounding the appropriate use of immunotherapy for the treatment of bladder cancer, the Society for Immunotherapy of Cancer (SITC) convened a Task Force of experts, including physicians, patient advocates, and nurses, to address issues related to patient selection, toxicity management, clinical endpoints, as well as the combination and sequencing of therapies. Following the standard approach established by the Society for other cancers, a systematic literature review and analysis of data, combined with consensus voting was used to generate guidelines. Here, we provide a consensus statement for the use of immunotherapy in patients with bladder cancer, with plans to update these recommendations as the field progresses.